ArticleThe Medical journal of Australia2025
The epidemiology of haemodialysis catheter infections in Australia, 2016-20: a prospective cohort study.
Article in The Medical journal of Australia, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Comprehensive management of hemodialysis catheter-related bloodstream infections: a narrative review.Frontiers in cellular and infection microbiology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
objectivesTo investigate the epidemiology in Australia of catheter-related infections in a national cohort of adults with kidney failure with incident haemodialysis central venous catheters (CVCs). STUDY
designCohort study nested within a cluster-randomised trial (REDUcing the burden of dialysis Catheter Complications, REDUCCTION); analysis of prospectively collected trial data, linked with Australian and New Zealand Dialysis and Transplant (ANZDATA) registry and state hospitalisations data.
settingThirty-four health services in Australia (excluding Western Australia) that provide chronic haemodialysis and participated in the REDUCCTION trial.
participantsAdults (18 years or older) with chronic kidney failure who received incident haemodialysis CVCs during 20 December 2016 - 31 March 2020.
main outcome measuresHospitalisation with any haemodialysis CVC infection; haemodialysis CVC-related bloodstream infections reported during the trial and verified by an independent panel.
resultsOur analysis included 3943 adults with chronic kidney failure; their mean age was 60.4 years (standard deviation, 15.5 years); 1556 were women (39.5%) and 485 were Aboriginal or Torres Strait Islander people (12.3%). Catheter-related infections were coded for 644 hospitalisations (24.5 per 100 patient-years; 95% confidence interval [CI], 22.6-26.4 per 100 patient-years); the incidence was higher among people under 55 years of age (adjusted incidence rate ratio [IRR], 1.55; 95% CI, 1.21-1.98) and those aged 55-70 years (adjusted IRR, 1.34; 95% CI, 1.05-1.70) than among people over 70 years of age. Community-onset haemodialysis catheter-related bloodstream infections were responsible for 159 hospitalisations (8.2% of 1938 infection-related hospitalisations); 57 of 650 infection-related hospitalisations of people under 55 years of age (8.8%), 62 of 640 of people aged 55-70 years (9.7%), and 40 of 648 of people over 70 years of age (6.2%). The median length of hospital stay with community-onset haemodialysis CVC-related bloodstream infections was ten days (interquartile range, 5-15 days), metastatic spread of infection was detected in twelve cases (7.5%), and four people died in hospital (2.5%); 40 removed haemodialysis CVCs did not require replacement. Nineteen of 121 hospitalisations for which the information was available included intensive care unit admissions (15.7%; median stay, 2.7 days; IQR, 1.1-4.6 days). The risk of haemodialysis CVC-related Staphylococcus aureus bloodstream infection declined with age (relative risk ratio, 0.65 per decade; 95% CI, 0.47-0.89).
conclusionsThe health burden of haemodialysis CVC infections in Australia is substantial, particularly among adults under 70 years of age.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.